Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Immunotherapy and Biomarkers, and Genetic factors in colorectal cancer.
Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions
Risk Factors for COVID-19–Related Hospitalization and Death in Patients With Cancer
Abstract CT109: A first-in-human phase 1 study of LY4050784, an oral, potent, and selective SMARCA2 inhibitor, in patients with advanced solid tumors with <i>SMARCA4</i> alterations (Trial in Progress)
Clinical strategies for lung cancer management: Recommendations from the Bridging the Gaps Lung Cancer Consensus Conference 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Early-Stage Lung Cancer: Using Circulating Tumor DNA to Get Personal
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications
Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression
Abnormalities on baseline chest imaging are risk factors for immune checkpoint inhibitor associated pneumonitis
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade
Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy
Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies
Meeting an un-MET need: Targeting MET in non-small cell lung cancer
Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma
Severity of COVID-19 in patients with lung cancer: evidence and challenges
A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.
Implementation of Advance Care Planning in Oncology: A Review of the Literature
Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings